Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents

BACKGROUND: While immune checkpoint inhibitors such as anti-PD-L1 antibodies have revolutionized cancer treatment, only subgroups of patients show durable responses. Insight in the relation between clinical response, PD-L1 expression and intratumoral localization of PD-L1 therapeutics could improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagemans, Iris M., Wierstra, Peter J., Steuten, Kas, Molkenboer-Kuenen, Janneke D. M., van Dalen, Duco, ter Beest, Martin, van der Schoot, Johan M. S., Ilina, Olga, Gotthardt, Martin, Figdor, Carl G., Scheeren, Ferenc A., Heskamp, Sandra, Verdoes, Martijn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811974/
https://www.ncbi.nlm.nih.gov/pubmed/35109860
http://dx.doi.org/10.1186/s12951-022-01272-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811974/
https://www.ncbi.nlm.nih.gov/pubmed/35109860
http://dx.doi.org/10.1186/s12951-022-01272-5

Ejemplares similares